The Colorado Blood Cancer Institute is advancing care for patients with blood and marrow disorders, as well as specific cancers through compassionate treatment, education and research. Our transplant program performs more than 275 transplants annually serving patients from Nebraska, Wyoming, New Mexico, Kansas, Utah, Montana, Arizona and Colorado. Very few transplant programs in the country can offer the level of experience and expertise provided by the physicians and staff at CBCI. The program's volume has grown steadily since 1991 having performed over 3500 transplant since inception. Our facilities are in the heart of Denver, Colo., and our patients come from all over the country.

We offer the Rocky Mountain Region's largest full-service blood and marrow transplant program, performing autologous transplants and allogeneic transplants as well as a full range of cellular therapies, including CAR T-Cell therapy, DLIs and photopheresis for Chronic Graft Versus Host Disease (cGVHD).

Our center offers treatments for hematological diseases and other disorders, including the following:

The program is a National Marrow Donor Program (NMDP) apheresis, collection and transplant facility, as well as a FACT-accredited program performing autologous, related donor and unrelated donor transplants and cord blood transplants.

CBCI’s research efforts are driven from a desire to broaden the scope of eligible transplant recipients. Through the use of nonmyeloablative or reduced intensity allogeneic transplants and cord blood transplants, we are able to broaden both the age and ethnicity of the patients we serve.

Our transplant team includes program psychologists, social workers, dietitians, advanced practice providers, medical assistants, financial and transplant nurse coordinators and oncology-certified registered nurses who support patients along their transplant journey. Additionally, we have a Long Term Follow Up Program to manage the possible complications of our allogeneic patients’ Graft Versus Host Disease (GVHD). Upon completion of transplant, we continue to follow patients and remain as a resource for our referring physicians whose patients have returned to their care.